Fingolimod (Gilneya) and disease activity

Reanalysis of previous trials show that taking fingolimod were four times more likely than those on placebo to show no evidence of disease activity (NEDA) as those on. NEDA defined as absence of relapses, no MRI lesions, no increase in brain volume loss and no disability progression. Reported at the ACTRIMS/ECTRIMS conference. Novartis press release Fingolimod (Gilneya) - A to Z of MS
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news